vs
Side-by-side financial comparison of Doximity, Inc. (DOCS) and NovoCure Ltd (NVCR). Click either name above to swap in a different company.
Doximity, Inc. is the larger business by last-quarter revenue ($185.1M vs $174.1M, roughly 1.1× NovoCure Ltd). Doximity, Inc. runs the higher net margin — 33.3% vs -40.9%, a 74.1% gap on every dollar of revenue. On growth, NovoCure Ltd posted the faster year-over-year revenue change (12.3% vs 9.8%). Over the past eight quarters, Doximity, Inc.'s revenue compounded faster (25.2% CAGR vs 7.6%).
Doximity is an online networking service for medical professionals. Launched in 2010, the platform offers its members curated medical news, telehealth tools, and case collaboration.
NovoCure Ltd is a global oncology company that develops and commercializes innovative Tumor Treating Fields (TTFields) therapy, a non-invasive wearable treatment using low-intensity electric fields to disrupt cancer cell division. Its approved therapies target glioblastoma, malignant mesothelioma and non-small cell lung cancer, serving patients across North America, Europe and Asia Pacific.
DOCS vs NVCR — Head-to-Head
Income Statement — Q3 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $185.1M | $174.1M |
| Net Profit | $61.6M | $-71.1M |
| Gross Margin | 89.9% | 77.6% |
| Operating Margin | 38.9% | — |
| Net Margin | 33.3% | -40.9% |
| Revenue YoY | 9.8% | 12.3% |
| Net Profit YoY | -18.1% | -107.3% |
| EPS (diluted) | $0.31 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $174.1M | ||
| Q4 25 | $185.1M | $174.3M | ||
| Q3 25 | $168.5M | $167.2M | ||
| Q2 25 | $145.9M | $158.8M | ||
| Q1 25 | $138.3M | $155.0M | ||
| Q4 24 | $168.6M | $161.3M | ||
| Q3 24 | $136.8M | $155.1M | ||
| Q2 24 | $126.7M | $150.4M |
| Q1 26 | — | $-71.1M | ||
| Q4 25 | $61.6M | $-24.5M | ||
| Q3 25 | $62.1M | $-37.3M | ||
| Q2 25 | $53.3M | $-40.1M | ||
| Q1 25 | $62.5M | $-34.3M | ||
| Q4 24 | $75.2M | $-65.9M | ||
| Q3 24 | $44.2M | $-30.6M | ||
| Q2 24 | $41.4M | $-33.4M |
| Q1 26 | — | 77.6% | ||
| Q4 25 | 89.9% | 75.8% | ||
| Q3 25 | 90.3% | 73.2% | ||
| Q2 25 | 89.2% | 73.9% | ||
| Q1 25 | 89.5% | 75.1% | ||
| Q4 24 | 91.6% | 79.2% | ||
| Q3 24 | 90.0% | 77.2% | ||
| Q2 24 | 89.3% | 77.0% |
| Q1 26 | — | — | ||
| Q4 25 | 38.9% | -23.2% | ||
| Q3 25 | 37.8% | -21.5% | ||
| Q2 25 | 37.4% | -24.9% | ||
| Q1 25 | 35.2% | -24.4% | ||
| Q4 24 | 47.4% | -39.3% | ||
| Q3 24 | 38.8% | -20.7% | ||
| Q2 24 | 36.4% | -22.3% |
| Q1 26 | — | -40.9% | ||
| Q4 25 | 33.3% | -14.1% | ||
| Q3 25 | 36.8% | -22.3% | ||
| Q2 25 | 36.5% | -25.3% | ||
| Q1 25 | 45.2% | -22.1% | ||
| Q4 24 | 44.6% | -40.9% | ||
| Q3 24 | 32.3% | -19.7% | ||
| Q2 24 | 32.7% | -22.2% |
| Q1 26 | — | — | ||
| Q4 25 | $0.31 | $-0.22 | ||
| Q3 25 | $0.31 | $-0.33 | ||
| Q2 25 | $0.27 | $-0.36 | ||
| Q1 25 | $0.31 | $-0.31 | ||
| Q4 24 | $0.37 | $-0.61 | ||
| Q3 24 | $0.22 | $-0.28 | ||
| Q2 24 | $0.21 | $-0.31 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $64.8M | $432.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $979.3M | $330.7M |
| Total Assets | $1.2B | $787.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $432.0M | ||
| Q4 25 | $64.8M | $93.5M | ||
| Q3 25 | $169.2M | $342.1M | ||
| Q2 25 | $137.3M | $149.6M | ||
| Q1 25 | $209.6M | $127.3M | ||
| Q4 24 | $165.3M | $163.8M | ||
| Q3 24 | $184.2M | $185.4M | ||
| Q2 24 | $111.4M | $164.8M |
| Q1 26 | — | $330.7M | ||
| Q4 25 | $979.3M | $340.5M | ||
| Q3 25 | $1.1B | $341.3M | ||
| Q2 25 | $1.0B | $349.4M | ||
| Q1 25 | $1.1B | $362.0M | ||
| Q4 24 | $1.0B | $360.2M | ||
| Q3 24 | $961.2M | $360.8M | ||
| Q2 24 | $913.6M | $361.8M |
| Q1 26 | — | $787.9M | ||
| Q4 25 | $1.2B | $804.3M | ||
| Q3 25 | $1.3B | $1.4B | ||
| Q2 25 | $1.2B | $1.2B | ||
| Q1 25 | $1.3B | $1.2B | ||
| Q4 24 | $1.2B | $1.2B | ||
| Q3 24 | $1.1B | $1.2B | ||
| Q2 24 | $1.1B | $1.2B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $60.9M | — |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | 0.99× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $60.9M | $-18.0M | ||
| Q3 25 | $93.9M | $20.6M | ||
| Q2 25 | $62.1M | $-15.9M | ||
| Q1 25 | $98.5M | $-35.7M | ||
| Q4 24 | $65.2M | $-3.5M | ||
| Q3 24 | $68.3M | $10.4M | ||
| Q2 24 | $41.2M | $-1.7M |
| Q1 26 | — | — | ||
| Q4 25 | — | $-22.9M | ||
| Q3 25 | — | $14.9M | ||
| Q2 25 | — | $-21.4M | ||
| Q1 25 | — | $-46.3M | ||
| Q4 24 | — | $-12.4M | ||
| Q3 24 | — | $-307.0K | ||
| Q2 24 | — | $-13.2M |
| Q1 26 | — | — | ||
| Q4 25 | — | -13.1% | ||
| Q3 25 | — | 8.9% | ||
| Q2 25 | — | -13.5% | ||
| Q1 25 | — | -29.9% | ||
| Q4 24 | — | -7.7% | ||
| Q3 24 | — | -0.2% | ||
| Q2 24 | — | -8.8% |
| Q1 26 | — | — | ||
| Q4 25 | — | 2.8% | ||
| Q3 25 | — | 3.4% | ||
| Q2 25 | — | 3.5% | ||
| Q1 25 | 0.0% | 6.8% | ||
| Q4 24 | 0.0% | 5.5% | ||
| Q3 24 | 0.0% | 6.9% | ||
| Q2 24 | 0.0% | 7.6% |
| Q1 26 | — | — | ||
| Q4 25 | 0.99× | — | ||
| Q3 25 | 1.51× | — | ||
| Q2 25 | 1.16× | — | ||
| Q1 25 | 1.58× | — | ||
| Q4 24 | 0.87× | — | ||
| Q3 24 | 1.55× | — | ||
| Q2 24 | 1.00× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
DOCS
| Subscription | $175.4M | 95% |
| Service Other | $9.7M | 5% |
NVCR
Segment breakdown not available.
